FINE HEALTH WITHOUT ESSILOR
09/04/19 -"The following chart shows how a lagging €42bn stock, EssilorLuxottica (Buy, France), can act as a brake to the otherwise brisk performance of a Health sector (excluding Pharmas, weighing €285bn). ..."
Pages
57
Language
English
Published on
09/04/19
You may also be interested by these reports :
25/04/24
BNP published better results than expected, thanks to a better outcome in CPBS, a strong cost discipline with notable opex reductions in CIB, the end ...
25/04/24
Swedbank was the last of the Swedish banks to report its Q1 results, posting a low-quality beat as much of it came from lower opex, which declined ...
25/04/24
• Net revenues were up by 1% to €7.8bn for Q1 24 compared to Q1 23 • Provision for credit losses rose by 18% to €439 for Q1 24 • Total expenses ...
25/04/24
The group released a good set of quarterly results enabling the management to reiterate its short- and mid-term RoTE objectives. This should ...